CTXR is Hottest Stock in Market, Much Larger Gains Ahead!

On Monday, NIA announced Citius Pharmaceuticals (CTXR) as its first ever Biotechnology Stock Suggestion and it immediately began to breakout big by gaining $0.53 or 14.1% to close at $4.29 per share on 9X higher than average volume!

Yesterday, CTXR announced that a 44 patient study was conducted in Brazil, Lebanon, and Japan for its Mino-Lok therapy in achieving microbiological eradication of infected central venous catheters (CVCs) and it showed 95% effectiveness as compared to 83% for the control! CTXR continued to build major momentum and gained another $0.37 or 8.7% to close at $4.64 per share on very strong volume!

NIA is 100% convinced that this is just the very beginning with much larger gains to come in the days/weeks ahead! CTXR’s current market cap at $4.64 per share remains extremely low at only $38.28 million. In the U.S. alone, Mino-Lok appears to be perfectly positioned to soon capture an unmet marketplace worth $750 million! At a very minimum, NIA strongly believes that CTXR deserves to immediately be trading with a market cap equal to 10% of its target market – especially now that CTXR is beginning Phase 3 trials for Mino-Lok and the FDA has granted it “Fast Track” status, making Mino-Lok eligible for priority review to shorten the FDA review process from ten months to only six months!

The CEO of CTXR is Myron Holubiak and from 1998 through 2001 he was the President of Roche Laboratories Inc., the U.S. subsidiary of Roche Holding AG (RHHBY) the world’s third largest pharma with a market cap of $203 BILLION! Most recently, from 2012 through 2016, Holubiak served as Chairman of BioScrip (BIOS) a $700 million enterprise value company with $900 million in revenue! He is currently on the Board of Directors of Assembly Biosciences (ASMB), a $560 million market cap company!

In NIA’s opinion, CTXR deserves to immediately begin trading with a market cap of $75-$100 million, which would value CTXR between $9 and $12 per share! If CTXR’s Phase 3 trials are successful and the company receives FDA approval for Mino-Lok, we look for it to quickly become a $300-$500 million market cap company trading for between $36 and $60 per share!

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from a third-party for covering CTXR of $20,000 cash. Never make investment decisions based on anything NIA says. This message is meant for informational and educational purposes only and does not provide investment advice.